Orexigen Obesity Drug Reduces Weight but Lower Than FDA Requirements
Submitted by Jason Ramsey on Fri, 01/09/2009 - 18:34
An experimental obesity drug Contrave by Orexigen Therapeutics Inc. (OREX. O) did not meet the mark set by the Food and Drug Administration leading to the company’s stock plummeting by 33.1 %.
Latest News
|
|
|
|
|
|
|
|
|
|
|
|
